Adverse effects associated with regadenoson myocardial perfusion imaging

J Nucl Cardiol. 2018 Oct;25(5):1724-1731. doi: 10.1007/s12350-018-1218-7. Epub 2018 Feb 21.

Authors

Efstathia Andrikopoulou¹, Fadi G Hage^{2

3}

Affiliations

¹ Sub-division of Non-Invasive Cardiovascular Imaging, Division of Cardiovascular Disease, Department of Medicine, Brigham and Women's Hospital, 75 Francis street, ABI L1-027, Boston, MA, 02115, USA. [email protected].
² Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
³ Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA.

PMID: 29468467
DOI: 10.1007/s12350-018-1218-7

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Myocardial Perfusion Imaging*
Nitroglycerin
Purines
Pyrazoles
Vasodilator Agents

Substances

Purines
Pyrazoles
Vasodilator Agents
regadenoson
Nitroglycerin